Mead Johnson to operate independently from Bristol-Myers

Bristol-Myers Squibb is divesting Mead Johnson Nutrition to concentrate on biopharmaceuticals. The deal allows Bristol-Myers' shareholders to "exchange some, none or all of their shares of Bristol-Myers Squibb common stock for shares of Mead Johnson common stock," the company said.

View Full Article in:

Chicago Tribune (tiered subscription model) · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care